October 2020.
elong.Life has expanded its digital clinical trial matching program to include patients with multiple sclerosis (MS). The technology uses advanced artificial intelligence (AI) that processes a patient’s medical data and determines which trials in its global database are appropriate. The app typically returns results, which are prescreened by a clinical trial coordinator, in less than two days. More than 8,000 cancer patients have used the program so far.
Belong.Life is a global healthtech provider of high-engagement patient communities and care platforms, supporting millions of patients worldwide.
Among Belong.Life’s brands are the world’s largest social and professional networks for cancer patients (Belong – Beating Cancer Together) and multiple sclerosis patients (BelongMS), as well as additional tailored communities for Psoriasis, Crohn’s , Obesity (select countries) and more.
With the launch of Dave, Belong.Life has introduced the world’s first real-time conversational AI oncology mentor for cancer patients.
All of Belong’s products and services are multilingual, HIPAA, GDPR and ISO compliant.
